# Quality of Life Outcomes After Endoscopic Cholesteatoma Surgery: A Prospective Cohort Study

**Authors:** Luana-Maria Gherasie, Viorel Zainea, Tamer Ebaied, Razvan Hainarosie, Corina Daniela Negrila, Andreea Rusescu, Irina-Gabriela Ionita, Catalina Voiosu

PMC · DOI: 10.3390/jcm15041556 · 2026-02-16

## TL;DR

This study shows that endoscopic surgery for cholesteatoma improves patients' quality of life and hearing outcomes effectively.

## Contribution

The study provides patient-reported quality of life data after endoscopic cholesteatoma surgery using validated measures.

## Key findings

- Quality of life scores improved significantly from baseline to 12 months post-surgery.
- Hearing improved substantially, with a significant reduction in the air-bone gap.
- High patient satisfaction scores were maintained at 6 and 12 months post-surgery.

## Abstract

Background: Cholesteatoma is a destructive middle ear lesion that compromises hearing and quality of life, for which endoscopic ear surgery (EES) has emerged as a minimally invasive alternative to microscopic approaches. While recurrence and audiological outcomes are frequently reported, patient-centered evaluations using validated patient-reported outcome measures (PROMs) remain limited. Objective: This study aimed to assess postoperative quality of life in patients undergoing exclusive endoscopic cholesteatoma surgery, using validated patient-reported outcome measures. Methods: We conducted a prospective observational cohort study in a tertiary referral center, enrolling 41 patients who underwent exclusive endoscopic cholesteatoma surgery over 20 months. Pre- and postoperative QoL was assessed using the Chronic Otitis Media Questionnaire-12 (COMQ-12) and the Glasgow Benefit Inventory (GBI). Results: COMQ-12 scores improved significantly from baseline (54.0 ± 4.2) to 12 months (10.2 ± 3.3; mean difference −43.8, 95% CI: −46.1 to −41.5; p < 0.001). GBI scores were consistently high, increasing from 82.6 ± 4.8 at 6 months to 84.1 ± 4.9 at 12 months (p < 0.001). Audiometric evaluation demonstrated a significant postoperative improvement, with the mean air–bone gap (ABG) decreasing from 52.1 ± 5.3 dB preoperatively to 26.4 ± 4.7 dB postoperatively (p < 0.001), indicating substantial closure of the conductive gap. Conclusions: Exclusive endoscopic cholesteatoma surgery yields robust QoL improvement, favourable hearing outcome, and recurrence rates similar to classic techniques at short-term evaluation.

## Linked entities

- **Diseases:** cholesteatoma (MONDO:0006530)

## Full-text entities

- **Genes:** CES1 (carboxylesterase 1) [NCBI Gene 1066] {aka ACAT, CE-1, CEH, CES2, HMSE, HMSE1}, CECR (cat eye syndrome chromosome region) [NCBI Gene 1055] {aka CES}
- **Diseases:** bone erosion (MESH:D014077), wound infections (MESH:D014946), hearing disability (MESH:D006311), tumor (MESH:D009369), ear disease (MESH:D004427), postoperative pain (MESH:D010149), chorda tympani injury (MESH:D014012), Cholesteatoma (MESH:D002781), mastoid disease (MESH:D008417), taste disturbance (MESH:D013651), epithelial (MESH:D009375), injury to (MESH:D014947), inflammation (MESH:D007249), Otitis (MESH:D010031), facial nerve palsy (MESH:D005155), ear cholesteatoma (MESH:D018424), middle ear lesion (MESH:D010033), CSF fistula (MESH:D005402), sensorineural hearing loss (MESH:D006319), Bleeding (MESH:D006470), hearing gain (MESH:D015430)
- **Chemicals:** COMQ (-), tranexamic acid (MESH:D014148)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942356/full.md

---
Source: https://tomesphere.com/paper/PMC12942356